Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises. (January 2021)

• Record Type: Journal Article
• Authors: Rezakhani, Leila; Kelishadrokhi, Ali Fatahian; Soleimanizadeh, Arghavan; Rahmati, Shima
• Is Part Of: Chemistry and physics of lipids. Volume 234(2021)
• Publication Date: 2021-01
• Subjects: MSC exsosomes -- Exosome based therapy -- covid-19; Lipids -- Periodicals; Lipids -- Periodicals; Lipides -- Périodiques; Lipids; Periodicals; Electronic journals; 547.77
• DOI: 10.1016/j.chemphyslip.2020.105009
• Languages: English
• ISSNs: 0009-3084

Abstract

Highlights: There are no commercially available effective antiviral medications or vaccines to deal with novel coronavirus disease (COVID-19). Exosomes carry complex cargo including bioactive which are transmitted to adjacent and distant cells. Due to their ability to deliver and exchange intracellular messages and interact with receiver cells, exosomes can applied in diseases treatment. Due to the specific structure of the exosomes various drugs can be inserted into them so they can be used in a variety of diseases as drug delivery. Abstract: There are no commercially available effective antiviral medications or vaccines to deal with novel coronavirus disease (COVID-19). Hence there is a substantial unmet medical need for new and efficacious treatment options for COVID-19. Most COVID-19 deaths result from acute respiratory distress syndrome (ARDS). This virus induces excessive and aberrant inflammation so it is important to control the inflammation as soon as possible. To date, results of numerous studies have been shown that mesenchymal stem cells and their derivatives can suppress inflammation. Exosomes function as intercellular communication vehicles to transfer bioactive molecules (based on their origins), between cells. In this review, the recent exosome-based clinical trials for the treatment of COVID-19 are presented. Potential therapy may include the following items: First, using mesenchymal stem cells secretome. Second, incorporating specific miRNAs and mRNAs into exosomes and last, using exosomes as carriers to deliver drugs.